Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

At OU, journey begins at Tech Development office

Get in Touch

By Jim Stafford

Copyright © 2014, Oklahoma Publishing Company

Oklahoma City-based Caisson Biotech, LLC, gave all Oklahomans a reason to celebrate last March when it signed a $!67 million partnering agreement with the pharmaceutical industry giant Novo Nordisk.

Caisson developed a patented heparosan-based drug delivery technology called HEPtuneTM that can be used for a variety of therapeutic areas, including diabetes care or inflammatory diseases such as Crohn’s disease and arthritis.

HEPtuneTM was developed in the laboratory of Paul DeAngelis, Ph.D., a Presidential Professor of Biochemistry and Molecular Biology at the University of Oklahoma College of Medicine.  He also serves as Chief Scientist for Caisson, which licensed the technology from OU and developed the lucrative drug delivery product.

Gina McMillen and Jim Bratton from the University of Oklahoma Office of Technology Development
Gina McMillen and Jim Bratton from the University of Oklahoma Office of Technology Development

For companies such as Caisson that license technologies created on any of OU’s three campuses, their journey begins with OU’s Office of Technology Development. The office is led by Jim Bratton, executive director, and Gina McMillen, director and employs a diverse staff with expertise in patenting, licensing and commercialization.

“I would say Caisson Biotech is our most recent big success story, in terms of revenue,” Bratton told me last week as we sat in a small conference room in the Three Partners Place building on OU’s South Research campus in Norman campus.

I was there to learn something about how OU’s process works as it negotiates licensing deals with companies and entrepreneurs with groundbreaking technology developed at the university.

For instance, how “user friendly” is OU for both researchers and companies seeking to license technologies?

“From a financial incentive standpoint we have a very favorable intellectual property policy,” Bratton said. “Most universities have a revenue sharing plan and allow a researcher to share in the licensing revenue.  OU took a very forward, positive and advantageous perspective in favor to the inventor, where the inventor receives 35 percent of all gross royalties received by the university,’’

Before any licensing deal is struck, however, it is preceded by a complicated due diligence process.

“Commercializing nascent innovation is nuanced and takes time,” Bratton said. “It’s our fiduciary obligation to the faculty inventors, the board of regents and the taxpayers to ensure the deal fits the university’s mission, protects academic freedoms and that the commercialization results in a benefit to the state and society.”

Often, the first challenge can be to determine whether a new concept is scalable and has true commercial potential.

That difficulty drove OU to collaborate with i2E, Inc., the Oklahoma Center for the Advancement of Science and Technology (OCAST), Cowboy Technologies and Oklahoma State University to launch the Oklahoma Proof of Concept Center.

Through the Proof of Concept Center, teams often composed of students as well as faculty/inventors seek to develop a prototype and reach out to potential customers over a 12-week period to gauge true market interest.

OU receives about 70 new discovery disclosures annually, about half of which come out of the Health Sciences campus.  Licensing activities for fiscal 2014 totaled $3.6 million, including $2.5 million generated by life science companies such as Caisson.

In addition to Caisson, other potential success stories are brewing from OU licensees such as Selexys Pharmaceuticals and Moleculera Labs. Both companies are based the University Research Park in Oklahoma City.

“These are overnight successes decades in the making,” Bratton said. “Tech transfer is risky, tough to do and takes time to get it right.  We are very pro entrepreneur here, and do everything we can to ensure that we are part of the company’s success and not the reason it fails.”

Click here to read the article at newsok.com.

 

Author

  • admin admin

More News

Loading...
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
Default Featured Image
OKBio
06.13.22

AscendBioVentures BIO

Read more
Default Featured Image
OKBio
06.13.22

Dean McGee Eye Institute BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E